{"name":"Guerbet","slug":"guerbet","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1995-01-01","label":"Ioxitol first approved","drug":"Ioxitol","drugSlug":"ioxilan","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Dotarem first approved","drug":"Dotarem","drugSlug":"gadoterate-meglumine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"Xenetix","genericName":"Xenetix","slug":"xenetix","indication":"Other","status":"marketed"},{"name":"DOTAREM","genericName":"DOTAREM","slug":"dotarem","indication":"MRI contrast enhancement for brain, spine, and body imaging","status":"marketed"},{"name":"Dotarem","genericName":"GADOTERATE MEGLUMINE","slug":"gadoterate-meglumine","indication":"Detection and visualization of BBB disruption/abnormal vascularity","status":"marketed"},{"name":"Dotarem (gadoterate meglumine)","genericName":"Dotarem (gadoterate meglumine)","slug":"dotarem-gadoterate-meglumine","indication":"Contrast-enhanced MRI of the brain, spine, and body in adults and pediatric patients","status":"phase_3"},{"name":"Dotarem®-enhanced MRI","genericName":"Dotarem®-enhanced MRI","slug":"dotarem-enhanced-mri","indication":"MRI enhancement of the brain, spine, and associated tissues","status":"marketed"},{"name":"Elucirem","genericName":"GADOPICLENOL","slug":"gadopiclenol","indication":"Detect and visualize lesions with abnormal vascularity with MRI","status":"marketed"},{"name":"Elucirem","genericName":"Elucirem","slug":"elucirem","indication":"Detect and visualize lesions with abnormal vascularity with MRI","status":"marketed"},{"name":"Gadoterate meglumine (Dotarem)","genericName":"Gadoterate meglumine (Dotarem)","slug":"gadoterate-meglumine-dotarem","indication":"MRI contrast enhancement for central nervous system imaging","status":"phase_3"},{"name":"Gadovist®/Gadavist®","genericName":"Gadovist®/Gadavist®","slug":"gadovist-gadavist","indication":"Contrast enhancement for MRI of the central nervous system (brain and spinal cord)","status":"marketed"},{"name":"Ioxitol","genericName":"IOXILAN","slug":"ioxilan","indication":"Other","status":"marketed"},{"name":"Lipiodol Ultra Fluid with surgical glues","genericName":"Lipiodol Ultra Fluid with surgical glues","slug":"lipiodol-ultra-fluid-with-surgical-glues","indication":"Radiographic visualization during surgical procedures","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Iodixanol 320 mgI/mL","genericName":"Iodixanol 320 mgI/mL","slug":"iodixanol-320-mgi-ml","indication":"Coronary and peripheral angiography","status":"marketed"},{"name":"Ioversol 320 mgI/mL","genericName":"Ioversol 320 mgI/mL","slug":"ioversol-320-mgi-ml","indication":"Contrast enhancement for coronary angiography and cardiac imaging","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Xenetix-CT perfusion imaging","genericName":"Xenetix-CT perfusion imaging","slug":"xenetix-ct-perfusion-imaging","indication":"CT perfusion imaging of the brain for acute stroke evaluation","status":"marketed"}]}],"pipeline":[{"name":"Xenetix","genericName":"Xenetix","slug":"xenetix","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DOTAREM","genericName":"DOTAREM","slug":"dotarem","phase":"marketed","mechanism":"DOTAREM is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.","indications":["MRI contrast enhancement for brain, spine, and body imaging","Contrast-enhanced MRI for detection and characterization of lesions in various tissues"],"catalyst":""},{"name":"Dotarem","genericName":"GADOTERATE MEGLUMINE","slug":"gadoterate-meglumine","phase":"marketed","mechanism":"Gadoterate enhances MRI image brightness by shortening T1 and T2 relaxation times in tissues.","indications":["Detection and visualization of BBB disruption/abnormal vascularity"],"catalyst":""},{"name":"Dotarem (gadoterate meglumine)","genericName":"Dotarem (gadoterate meglumine)","slug":"dotarem-gadoterate-meglumine","phase":"phase_3","mechanism":"Gadoterate meglumine is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.","indications":["Contrast-enhanced MRI of the brain, spine, and body in adults and pediatric patients","Contrast-enhanced MRI for detection and characterization of lesions in various organs"],"catalyst":""},{"name":"Dotarem®-enhanced MRI","genericName":"Dotarem®-enhanced MRI","slug":"dotarem-enhanced-mri","phase":"marketed","mechanism":"Dotarem is a gadolinium-based contrast agent that enhances MRI signal by altering the magnetic properties of nearby water molecules in tissues.","indications":["MRI enhancement of the brain, spine, and associated tissues","MRI enhancement of the body (chest, abdomen, pelvis)","MRI angiography"],"catalyst":""},{"name":"Elucirem","genericName":"GADOPICLENOL","slug":"gadopiclenol","phase":"marketed","mechanism":"Gadopiclenol enhances MRI image brightness by altering water proton relaxation rates in a magnetic field.","indications":["Detect and visualize lesions with abnormal vascularity with MRI"],"catalyst":""},{"name":"Elucirem","genericName":"Elucirem","slug":"elucirem","phase":"marketed","mechanism":"Small molecule","indications":["Detect and visualize lesions with abnormal vascularity with MRI"],"catalyst":""},{"name":"Gadoterate meglumine (Dotarem)","genericName":"Gadoterate meglumine (Dotarem)","slug":"gadoterate-meglumine-dotarem","phase":"phase_3","mechanism":"Gadoterate meglumine is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.","indications":["MRI contrast enhancement for central nervous system imaging","MRI contrast enhancement for body imaging including liver, kidney, and other organs"],"catalyst":""},{"name":"Gadovist®/Gadavist®","genericName":"Gadovist®/Gadavist®","slug":"gadovist-gadavist","phase":"marketed","mechanism":"Gadovist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.","indications":["Contrast enhancement for MRI of the central nervous system (brain and spinal cord)","Contrast enhancement for MRI of the body (organs, tissues, and vasculature)"],"catalyst":""},{"name":"Iodixanol 320 mgI/mL","genericName":"Iodixanol 320 mgI/mL","slug":"iodixanol-320-mgi-ml","phase":"marketed","mechanism":"Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and body cavities by absorbing X-rays.","indications":["Coronary and peripheral angiography","Urography and intravenous pyelography","Venography","Computed tomography (CT) imaging"],"catalyst":""},{"name":"Ioversol 320 mgI/mL","genericName":"Ioversol 320 mgI/mL","slug":"ioversol-320-mgi-ml","phase":"marketed","mechanism":"Ioversol is a non-ionic, iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.","indications":["Contrast enhancement for coronary angiography and cardiac imaging","Contrast enhancement for peripheral vascular angiography","Contrast enhancement for cerebral angiography","Contrast enhancement for CT imaging of the abdomen, pelvis, and thorax"],"catalyst":""},{"name":"Ioxitol","genericName":"IOXILAN","slug":"ioxilan","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lipiodol Ultra Fluid with surgical glues","genericName":"Lipiodol Ultra Fluid with surgical glues","slug":"lipiodol-ultra-fluid-with-surgical-glues","phase":"marketed","mechanism":"Lipiodol Ultra Fluid is an iodized poppy seed oil contrast agent that provides radiographic visualization and can be combined with surgical adhesives for hemostasis and tissue sealing during surgical procedures.","indications":["Radiographic visualization during surgical procedures","Hemostasis and tissue sealing in surgical applications","Interventional radiology guidance"],"catalyst":""},{"name":"Xenetix-CT perfusion imaging","genericName":"Xenetix-CT perfusion imaging","slug":"xenetix-ct-perfusion-imaging","phase":"marketed","mechanism":"Xenetix is an iodinated contrast medium that enhances visualization of blood perfusion in tissues during CT imaging by increasing radiodensity in vascular and tissue compartments.","indications":["CT perfusion imaging of the brain for acute stroke evaluation","CT perfusion imaging of the heart for myocardial ischemia assessment","CT perfusion imaging of solid organs for tumor characterization and tissue viability assessment"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMGZFTzZobVQ1LUJQck5MVEp5U0xWTjFoclRUaXhCX3NmcS1FdVY3eGRac3VCekdXVUJDbjJEaWlRQWctbXZpSkZlOW1KV2VJdE4zTjhMV0FDQzBNX1V5Q3lBMTIxNmRZT1hKVmhhSS05c2ZxLVZoVzdlX05FSFR4SmpKTE9FZGFTcEt1UWVZal9qNThBeDlwUl9ZVDFtTUc5RjBHWHk3cW1PYjg?oc=5","date":"2026-03-17","type":"earnings","source":"The Business Journals","summary":"Raleigh factory violations drag down French firm's revenue - The Business Journals","headline":"Raleigh factory violations drag down French firm's revenue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNVGVBTGhjbVExcFVPdjNhMkNuTjNfUGc2NF9zVDFoY1R3YWFzSkF2bExsNWo5OFE3Ylc0WlNoSzFXNlNoV0xkc1BTaVg0a09mQ2dSUlVaMFlBaFVhcFdOZ0xOckpSR2pjMHdhLVVzUVN6SFdtZzM0NlVZMzdrUndBWG5pcG0zakp5aHo2T0RqYmhEZGs2QUxyNHRDLWpGX3YxdHVfMURzX3NvMWxFS0tXaHhmWlp0NzRtdWc?oc=5","date":"2026-03-11","type":"pipeline","source":"GlobeNewswire","summary":"GUERBET : Change in Guerbet’s Board of Directors. - GlobeNewswire","headline":"GUERBET : Change in Guerbet’s Board of Directors.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQMmZ6SElDX3FYOWRwUExNeXFoYXJxNzU3OHNwUk9BVldyQ3RnVlJ6amp0emx1Rm9TQUViTDJ6Nkw1V3RodGR2TjY5YnpqV2szdlFSaGFBQU1YNUNOZWE4NllMQTJXQk9WaU1oT0lZZDd3OENxVDdJWGllb05PdUpRUkNYcnZnZ1NENDhkM20zdTRHSGdHMzBCaUNoNnQ2dmZ4bWVtYTVyT1ZTWWdCaXBULVhLZFBNTkdZWG5JX2lTMXlNM3Ftcml0SQ?oc=5","date":"2026-01-28","type":"pipeline","source":"GlobeNewswire","summary":"Guerbet: Karim Boussebaa appointed Chief Executive Officer - GlobeNewswire","headline":"Guerbet: Karim Boussebaa appointed Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNUVViSG9LdC16SmdMb3pOUnNQZXh4TGVLU3cza1IwTEoyTEt5UjJVaS1xVXp4SC1LYkZJekVORERJeVk3YmNlZEdiWG1LZFNTQWRRdTNNR2NZRjQ3WjZTZGNEMmpmTFZRa2JYcS1KNjg2WWs1MmtYeDVFWDZJTFAyVWw3SEJ3MUxWU3hnS3ZEcnNzNkJkVTRfM29VTnJhTVFSVFVJa0tqZ1BBMm1YWjVPWFpITE9aekVIbDBJQg?oc=5","date":"2026-01-26","type":"pipeline","source":"NAVLIN DAILY","summary":"Seven Firms, Including Sanofi & Ipsen to Launch New Industry Body After Leem Exit - NAVLIN DAILY","headline":"Seven Firms, Including Sanofi & Ipsen to Launch New Industry Body After Leem Exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQVkg2eW1CdkFHMTNyUjZDSlBBbU1VTzdpd2RuQlZEb2ZqNHNvcFpxb0lZX0IzSTNVZ3g1bmR6WE9LRmp5SlFUbnE5SWIyWjFNNkxkam43SVVNOHY4a3NGRHhfQ1V3Ml9ZN0M4LWQtMXMwWVQtWENXRUdKSllfOWFRUFR4WmE0dXJRVW5OU2dqc09DZ2s3amlrM1NGWmJmZ0UyYm1vcw?oc=5","date":"2025-12-10","type":"pipeline","source":"The Business Journals","summary":"Violations at Raleigh plant dent pharma company's financial outlook - The Business Journals","headline":"Violations at Raleigh plant dent pharma company's financial outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxOb1NoeWd4V2ZFVUs0dlMwRlRNYUdTdGdwQ0VKZ1g1aFI0aDEyS2NUaF9Qa2JGckt4S05aRHlqUDBINy1lZmRPc0kxTGVzN08yeElnUGJnM1hYdDhqNGhtcG1hWnRUSmRlREhnVDRhcG96ZG1GNXBsTWJFbmVNNWJaN3FjQW1qNk8tNURhQjFNS1ZvVm11QnFDQkhWaUxXVUV4NF93ZERTVlBUbkJOMEUta2lQcFpGM1NXTDRwTElMWWhRektqVnZlOUwxWmk3a1E5a0E2dXk5VmNhU2JoWHlncWd6MHVpZjdvZ24zaU5kUlBCQ0k4eElkXzhuOHJDY1BzeTNGN0poOXFJSTdJcE1iQg?oc=5","date":"2025-10-23","type":"earnings","source":"GlobeNewswire","summary":"Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025. - GlobeNewswire","headline":"Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5lT3BiSWtFWW1rOVlJRmxXY25zYkJYZV9XeHNhdHVrRkZGcEZtaENjUk4tQnM0NjNOM21JanR3N05WcDhWMjdFd0d4b0NxRjBPbldSd1h0RHRzb3haamVxOGZ2VQ?oc=5","date":"2025-09-23","type":"pipeline","source":"The Pharma Letter","summary":"BetaGlue Therapeutics - The Pharma Letter","headline":"BetaGlue Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNS041OXpEZ1FDdU1mdGRJLUd6dV9GTnFpR0k4Q25lbFdTV1NMWGZOQVMzbjBzT1otSGdMbUdYVDRoS01KRkVvOHNSRkRJQ0c4dXgxcVZNX3hXRnBqdWlvZVdCa1J6R0lLLVQ5Skxvamg5RWJWMG1wR3MxUDVKbGRERjBDSmlibkRkelliZWp0cEdBTjd4QXlta3pYZ0J3dlhFUFgzZnBfMVZON1pfM2Rpdk1Zc0pkWmVONEhUYmJPa09zT0daSWc?oc=5","date":"2025-04-04","type":"pipeline","source":"AuntMinnie","summary":"China limits exports of rare earth elements, targets CT x-ray tubes - AuntMinnie","headline":"China limits exports of rare earth elements, targets CT x-ray tubes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOUVdaZlFFU1g1N2k2dFdGVnd6QVBhYWFfaWFXOVNYRkFnRC1VbDBlaGpXSnptTWkxV3Z2Qk9MN2M4QWhZcmFMaFIyV2FqR2pZUFhxSlBWRVJKZTFVMEdfMXF6ZGR6d2h2bVBZSllwX0c1NzNCVEJpUEQ0Q1JXdDFoZ2FvNTMwR2R4TnVIU0ZOTTB0X1IxVTVDQzBpZG5YeE9nTDZPbWRwX0ZKNGFQcHF2V1NJdmdFMFVwdDhYMEYtZkZCNEJHNEp0VXBR?oc=5","date":"2024-10-29","type":"pipeline","source":"European Medical Journal","summary":"Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond - European Medical Journal","headline":"Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNQ1dnd0xqMUJNeTBKX0M0X01WX2ctamVRZlZTY3pPLUVEUGVjR0VHMDNjUmlzVlI3NUc3S0dBTjBXQWp1czdGbW1VdkxTMmtfSVhaSXg0TERUSFhwQVk1OVVQMGZnSUlPdXM1ZEhsVTdkV2NQNk96M2tvMWdodDRTc29Iem91VnRRd3V4SVZ4cFZ1WTN2Q2hMQVc5THRHVi1Md2NaNE5BM25NY0k4SHREOExmdlNNT3l1UU8tbmJYVUJUMnAxM0JpZHBrWEh6dHY3cUY5WG5RVnJIQ2JaNDZ0ZE81U1ptbEF3aWU5dzhDRFM0cVBsdTg2VDFyR3l3Z0praUN0bktsWHZQY0h1dGItN2FqUVVLNUJKV3pjN0MzeGJ2ZHd0NmJCZTVRR0l5akdIOWhKdTlNTm9CajdBcUdMMQ?oc=5","date":"2023-02-02","type":"pipeline","source":"PR Newswire","summary":"Guerbet Releases First Production Batch of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI) - PR Newswire","headline":"Guerbet Releases First Production Batch of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZVhQa05faTFJT1JlZlMzckVRMUktUFlkODl5WTUyWXBXVHhIS09UY25mRWVXRThpRzVNQXpUano1dHFCNkZfd2tNM01RRXdUVDdHeEpaSFdtLWtkWmo4TG1PbDF3M3hDNWRweXlKR2swXzVRRDJ4ZVNIVC0yTnk0aE44d3BOaGZzQWtuUk1ZcnNSYnJHY2xXc0tnZGJZTS15Q1dDRDE0ZnVwTUE?oc=5","date":"2015-12-06","type":"regulatory","source":"Imaging Technology News","summary":"Guerbet Receives FDA Approval for Lipiodol Contrast Agent Manufacturing Plant - Imaging Technology News","headline":"Guerbet Receives FDA Approval for Lipiodol Contrast Agent Manufacturing Plant","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbnA4RU52MFZLakJ3ZjI4Ujcwb0FzRHdpQjRXU3hTa1FmWkc2X1BzRkhFN1FVQzFlTTdSMXJySXpxS2p2dDRSSGtqZWp6NGRTei1RTkR3dWpYZzBUSlpYLXp1ZXFJUi1mdHdxemhxMmt0cmJlZmJ0Vk5YQVB1TkNhdDc4OE8zdlhXVmxIRE5yZTd2bmxEVWMxQTVfT1NTYXdjZXBSbGVDUnB6cFZmQzIxR29mZ2VYajI1?oc=5","date":"2015-07-29","type":"deal","source":"dicardiology.com","summary":"Guerbet Group Acquires Mallinckrodt Contrast Media and Delivery Systems Business - dicardiology.com","headline":"Guerbet Group Acquires Mallinckrodt Contrast Media and Delivery Systems Business","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"marketed":12,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}